Table 2.

Baseline characteristics of included studies

Study	Trial acronym	Age, y	Male	HT	DM	Smoking
Jolly et al. [8], 2024	CLEAR	61 ± 10	80	46	18	41
Kelly et al. [9], 2024	CONVINCE	66 ±10	70	65	22	22
Li et al. [10], 2024	CHANCE-3	69 ±11	62	77	32	24
Khiali et al. [20], 2024	N.A.	60 ±10	73	55	0	39
Bouleti et al. [21], 2024	CONVERT-MI	60 ±10	80	31	13	43
Akrami et al. [23], 2021	N.A.	57 ± 8	69	45	24	41
Nidorf et al. [24], 2020	LoDoCo2	66 ± 9	85	51	23	12
Tong et al. [25], 2020	COPS	60 ±10	79	50	19	35
Shah et al. [26], 2020	COLCHICINE-PCI	66 ± 10	94	92	58	22
Hennessy et al. [27], 2019	LoDoCo-MI	61 ± 13	77	47	22	60
Tardif et al. [28], 2019	COLCOT	61 ± 11	81	51	20	30
Akodad et al. [29], 2017	COLIN	60 ± 12	80	43	14	70
Nidorf et al. [30], 2013	LoDoCo	66 ± 9	89	NA	30	5
Raju et al. [31], 2012	COOL	57 ±10	89	43	16	44

Data are presented as mean ± standard deviation or % unless otherwise indicated.

DM diabetes mellitus, HT hypertension, MACE major adverse cardiovascular events, NA not applicable, y years